logo

This website uses cookies to ensure you get the best experience on our website.

Read through the Privacy Policy to understand better

 Go Back

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulgent Genetics, Inc. (FLGT)

By AP News - Nov 18, 2022, 02:12 PM ET
Last Updated - Aug 01, 2024, 12:21 AM EDT
FLGT_building
Fulgent released its second quarter 2022 financial results, disclosing that the SEC was conducting an investigation into certain Exchange Act reports for 2018 through the first quarter of 2020. This came after the Company received a civil investigative demand issued by the U.S. Department of Justice “related to its investigation of allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 21, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT ) securities between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”)

LOS ANGELES--(BUSINESS WIRE)--Nov 18, 2022--

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 21, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT ) securities between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”).

Sponsored

If you are a shareholder who suffered a loss, click here to participate.

On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC was conducting an investigation into certain Exchange Act reports for 2018 through the first quarter of 2020. This came after the Company received a civil investigative demand issued by the U.S. Department of Justice “related to its investigation of allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law.”

By continuing to use this site, you agree to our terms and conditions
Sponsored
Sponsored
Sponsored
Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
    Phone: +1 (425) 414-0184
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
    Phone: +91 80 4902 2100
4.2 20250324